AZIN1 (Antizyme Inhibitor 1) Drug Discovery Landscape & Assay Solutions
- By admin
- 29 Sep 2026
- Comments
Targeting Polyamine Metabolism in Cancer: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatocellular Carcinoma, Fibrosis, and Beyond.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AZIN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | AZIN1 WT & Mutant Proteins (including S367G, R84A, L93A). High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 expressed. | View AZIN1 Products |
| Gene Delivery | AZIN1 Premade ORF Lentivirus (CMV promoter, Puromycin selection). Ready for stable cell line generation. | View AZIN1 Products |
| Benchmark Ab | Anti-AZIN1 Recombinant positive control for target validation. | View AZIN1 Products |
| Validator | AZIN1 siRNA Set (3 target-specific + 1 control) for knockdown verification and specificity controls. | View AZIN1 Products |
| Related Target A | ADAR1 – RNA editing enzyme driving the oncogenic AZIN1 S367G variant. | View ADAR1 Products |
| Related Target B | OAZ1 – Direct binding partner negatively regulated by AZIN1. | View OAZ1 Products |
| Related Target C | ODC1 – Downstream effector of the polyamine pathway. | View ODC1 Products |
| Related Target D | AZIN2 – Tissue-specific paralog; critical for selectivity screening. | View AZIN2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Targeting RNA-edited variant (S367G) | Ser367Gly mutant proteins available alongside WT for selectivity and PPI screening. Also includes interface mutants (R84A, L93A) for SAR. |
| PPI Disruption (AZIN1-Antizyme) | High-purity AZIN1 WT and OAZ1 proteins (>95% pure) for SPR/AlphaScreen; native conformation via HEK293 expression. |
| Selectivity vs. Paralog AZIN2 | Ortholog-specific proteins (Human AZIN1 vs AZIN2) with distinct N-terminal sequences verified by Mass Spec. |
| Intracellular Target Engagement | Premade lentivirus for stable overexpression cell lines; compatible with CETSA. |
| Off-target Polyamine Pathway Effects | Complete pathway panel (ODC1, OAZ1, SAT1, AZIN2) available for counter-screening. |
| Lack of Specificity Controls | Validated siRNA (3 target-specific + 1 control) for knockdown verification and rescue experiments. Clinical benchmark antibodies available. |
Live AZIN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The targeting of polyamine metabolism via AZIN1 represents an emerging strategy in oncology and fibrotic diseases. As the field moves beyond direct ODC inhibitors (DFMO) toward upstream regulatory nodes, AZIN1 has emerged as a critical vulnerability in hepatocellular carcinoma (HCC) and hepatic fibrosis. The critical role of ADAR1-mediated RNA editing (AZIN1 Ser367Gly) in driving oncogenic polyamine synthesis has shifted R&D focus toward mutant-specific conformations. The current landscape is characterized by early-stage small molecule programs targeting the AZIN1-antizyme protein-protein interaction (PPI), with increasing interest in PROTAC-based degradation and RNAi/ASO strategies. As first-generation inhibitors enter preclinical validation, the next wave of R&D is targeting combination approaches with immunotherapy and metabolic pathway inhibitors to overcome compensatory polyamine uptake mechanisms. The race for AZIN1 therapeutics is intensifying, with early-stage players shifting from basic polyamine inhibitors to targeted PPI modulators and PROTACs that selectively suppress oncogenic polyamine synthesis while sparing normal cellular functions.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / PPI Inhibitor | Preclinical/Academic Consortia, Early biotech | Hepatocellular Carcinoma (HCC), Hepatic Fibrosis | PPI Disruption Assay (Need high-purity AZIN1 + OAZ1 proteins; WT and S367G mutant) |
| PROTAC / Degrader | Early-stage Biotech, E3 ligase platform companies | Colorectal Cancer, Gastric Cancer, Solid Tumors | Ternary Complex Formation (Need AZIN1 mutants with intact ligase binding) |
| RNAi / ASO / Antisense Oligonucleotide | Emerging Startups, Ionis, Wave Life Sciences | Solid Tumors, Liver Fibrosis | Knockdown/Target Engagement Assay (Need siRNA and validated cell lines; lentivirus for rescue) |
| Combination (AZIN1i + ODCi) | Translational research groups | Polyamine-addicted cancers | Pathway Panel Screening (Need ODC1, AZIN2 for selectivity) |